Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA6 | P23280 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30690139 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HSD17B10TDP1LOXBCAT2 | |
| SCHEMBL8106699 | 0.87 | LOX (0.47) | ALDH1A1LOXBCAT2HSD11B1KDM4E | |
| SCHEMBL250199 | 0.87 | ALDH1A1 (0.55) | ALDH1A1HSD17B10TDP1HSD11B1GAA | |
| Hydrochloric Acid SCHEMBL7002220 | 0.86 | ALDH1A1 (0.48) | ALDH1A1HSD17B10TDP1PTGS2 | |
| SCHEMBL10846828 | 0.79 | TRPV4 (0.40) | ALDH1A1HSD17B10TDP1HSD11B1KDM4E | |
| SCHEMBL10415459 | 0.79 | GAA (0.50) | ALDH1A1HSD17B10TDP1HSD11B1GAA | |
| SCHEMBL1952210 | 0.76 | PSIP1 (0.48) | ALDH1A1HSD17B10TDP1HSD11B1KDM4E | |
| SCHEMBL29707959 | 0.76 | PSIP1 (0.48) | ALDH1A1HSD17B10TDP1HSD11B1KDM4E | |
| SCHEMBL9360977 | 0.75 | TDP1 (0.44) | ALDH1A1HSD17B10TDP1KDM4EGAA | |
| SCHEMBL30950298 | 0.75 | ALDH1A1 (0.44) | ALDH1A1HSD17B10TDP1HSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| JP-11335348-A | — | — | None | — | — | JP | disclosed |
| EP-3427728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3796975-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-2925744-B1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2020-12-30 | — | — | EP | disclosed |
| US-10730828-B2 | N-hydroxylsulfonamide derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| CN-105919987-B | N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives and uses thereof | 约翰斯霍普金斯大学 | 2020-04-03 | — | — | CN | disclosed |
| EP-2888251-B1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INST (AU) | 2019-04-24 | — | — | EP | disclosed |
| EP-2509941-B1 | N-ACYLATED HYDROXYLAMINE DERIVATIVES AND O-ACYLATED HYDROXYLAMINE DERIVATIVES | UNIV JOHNS HOPKINS (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-1997036580-A1 | AMIDINOHYDRAZONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| US-5091529-A | HERBICIDAL SUBSTITUTED SULPHONYLAMINOAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
| US-5021082-A | Pre=and postemergent | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-04 | — | — | US | disclosed |
| EP-0419831-A2 | Substituted sulfonylaminoazoles | BAYER AG (DE) | 1991-04-03 | — | — | EP | disclosed |
| EP-0094821-B1 | PROCESS FOR THE NUCLEOPHILIC SUBSTITUTION OF UNACTIVATED AROMATIC AND HETEROAROMATIC SUBSTRATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-08-08 | — | — | EP | disclosed |
| US-4941912-A | Herbicidal substituted sulphonylaminoazoles | BAYER AKTIENGESELLSCHAFT (DE) | 1990-07-17 | — | — | US | disclosed |
| EP-0330959-A2 | Substituted sulphonyl amino azoles | BAYER AG (DE) | 1989-09-06 | — | — | EP | disclosed |
| US-4783285-A | CATALYZED BY ACYCLIC OR CYCLIC POLYETHER | E. I. DUPONT DE NEMOURS AND COMPANY (US) | 1988-11-08 | — | — | US | disclosed |
| US-4683091-A | Process for the nucleophilic substitution of unactivated aromatic and heteroaromatic substrates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
| EP-0094821-A1 | Process for the nucleophilic substitution of unactivated aromatic and heteroaromatic substrates | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730828-B2 | N-hydroxylsulfonamide derivatives as nitroxyl donors | TNNI3, TNNT2, TNNC1 | ALDH1A1 1256/4885HSD17B10 354/4885TDP1 1397/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | ALDH1A1 240/4885HSD17B10 594/4885TDP1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.